Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14511060 | 0.93 | MEN1 (0.40) | KDM4EMEN1KMT2AHIF1AL3MBTL1 | |
| SCHEMBL14536651 | 0.92 | MEN1 (0.39) | KDM4EMEN1KMT2AHIF1AL3MBTL1 | |
| Gsk-364735 SCHEMBL5545304 | 0.88 | KDM4E (0.53) | KDM4EMEN1KMT2AHIF1AL3MBTL1 | |
| Gsk-364735 SCHEMBL5545803 | 0.87 | KDM4E (0.52) | KDM4EMEN1KMT2AHIF1AL3MBTL1 | |
| SCHEMBL6062341 | 0.86 | KDM4E (0.48) | KDM4EMEN1KMT2AHIF1AL3MBTL1 | |
| SCHEMBL5545319 | 0.85 | KDM4E (0.34) | KDM4EMEN1KMT2AHIF1ANPC1 | |
| SCHEMBL4906293 | 0.84 | KDM4E (0.48) | KDM4EMEN1KMT2AHIF1AL3MBTL1 | |
| SCHEMBL4901060 | 0.83 | KDM4E (0.43) | KDM4EMEN1KMT2AHIF1AL3MBTL1 | |
| SCHEMBL4591218 | 0.82 | KDM4E (0.45) | KDM4EMEN1KMT2AHIF1AL3MBTL1 | |
| SCHEMBL4575790 | 0.82 | KDM4E (0.45) | KDM4EMEN1KMT2AHIF1AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-8691991-B2 | 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | KDM4E 1268/4885MEN1 4802/4885KMT2A 502/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | KDM4E 1255/4885MEN1 4837/4885KMT2A 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.